Momo Kamei

A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8+ T Cells

A. Kawada, K. Matsuo, O. Yoshie, 2018, Front. Immunol..

Transcutaneous immunization with a highly active form of XCL1 as a vaccine adjuvant using a hydrophilic gel patch elicits long-term CD8+ T cell responses.

A. Kawada, N. Okada, K. Matsuo, 2020, Journal of pharmacological sciences.

Recent Progress in Dendritic Cell-Based Cancer Immunotherapy

K. Matsuo, O. Yoshie, T. Nakayama, 2021, Cancers.